By

CR2O
March 19, 2021

CR2O to manage First-in-Human trial with Dyadic’s SARS-CoV-2-S-RBD vaccine candidate DYAI-100

CR2O is proud to announce today it will manage and further support the clinical and preclinical development of DYAI-100, Dyadic’s C1 produced SARS-CoV-2-S-RBD vaccine candidate. The first-in-human trial with DYAI-100...
Read More
December 1, 2020

CR2O profiled in Biotech NEWS and Life Sciences

Dutch industry magazine Biotech NEWS and Life Sciences has profiled CR2O in their 2020 Winter edition. Biotech NEWS and Life Sciences is a national magazine reporting on trends and news within health...
Read More
November 7, 2020

H2020 awards contract to ENDFLU, CR2O coordinated vaccine trial

The EU Research and Innovation programme HORIZON 2020 has awarded a contract to a consortium that aims towards a next generation influenza vaccine to protect citizens worldwide (an EU-India collaboration)....
Read More
,
June 10, 2020

GLORIA aims to prove chronic low dose glucocorticoids are highly effective and safe in elderly patients

The EU Research and Innovation programme HORIZON 2020 has awarded contract worth up to 6 million euro’s to consortium led by Amsterdam Medical Center under grant agreement No 634886. GLORIA...
Read More
,
April 9, 2020

H2020 awards contract to develop a monoclonal antibody against COVID-19

The EU Research and Innovation programme HORIZON 2020 has awarded a contract worth up to 3 million euro’s to a European consortium led by ErasmusMC in collaboration with Harbour Antibodies...
Read More
,
March 5, 2020

Update COVID-19: Safeguarding health and safety

As a result of the COVID-19 pandemic, CR2O has adapted its contingency plan aimed to guarantee the safety and well-being of patients, employees, clients and continuity of our services.By following...
Read More
,
January 9, 2020

ISOLDA aims at the development of improved vaccines against viral infections for older adults

The EU Research and Innovation programme HORIZON 2020 has awarded a contract worth up to 6 million euro’s to a consortium led by Stiftung Tieraerztliche Hochschule Hannover (TiHo), aimed at...
Read More
,
August 5, 2019

CEPI awards contract worth up to US$12.5 million to consortium led by Wageningen Bioveterinary Research to develop a human vaccine against Rift Valley fever

Wageningen Bioveterinary Research (WBVR), part of Wageningen University & Research, and the Coalition for Epidemic Preparedness Innovations (CEPI) have announced a new partnering agreement. With support from the European Union’s...
Read More
,
September 17, 2018

Product Development and Clinical Investigation of a MERS-CoV Vaccine based on highly efficient scalable recombinant MVA technology

CEPI awarded a program which is aimed at the manufacturing and stockpiling of clinical supplies of MVA-MERS-S and the concomitant clinical development to a stage where outbreak deployment readiness is...
Read More
,
1 2